<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
   <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">

</head>


<body>
<div class="uk-container">
    <div class="chapter-header">
        <div class="header-title">
            <div>
                <img src="ic_chart.svg"  class="ic_chapter_icon">
            </div>
            <p class="chapter-title">14. What to start: Choice of TB Therapy and Antiretroviral Therapy (ART) when treating Co-infected Patients</p>
        </div>
        <p> <span class="view-in-chapter-highlight"> View in chapter → <span> <a href="5_treatment_of_current_(active)_disease_therapy__f__tb_and_hiv.html#table14"> Antiretroviral Therapy (ART) and Treatment of Persons Living with HIV and Active TB </a></p>
        <p class="last-updated"><i>Last Updated June 2024</i></p>
    </div>
    <hr>
    <div class="uk-overflow-auto"
         id="table_14_what_to_start_choice_of_tb_therapy_and_antiretroviral_therapy_(art)_when)treating_co-infected_patients">
         <p class="highlight">
            <strong>
                Principle: Despite Drug Interactions, a Rifamycin (Rifampin or Rifabutin) Should Be Included in TB Regimens for Patients Receiving ART, with Dosage Adjustment if Necessary
            </strong>
         </p>

         <div class="uk-tabs-container">
            <ul class="tabs">
                <li ><button class="tab active-tab" onclick="switchTab(0, event)">Option 1</button></li>
                <li ><button class="tab" onclick="switchTab(1, event)">Option 2</button></li>
                <li ><button class="tab" onclick="switchTab(2, event)">Pregnant Women</button></li>
            </ul>
         </div>

         <div id="option-content0" class="tab-content option-content active-option">
            <p>
                <strong>
                    Integrase-based ART regimens. Dolutegravir is the preferred integrase for TB/HIV co-infection treatment.
                </strong>
            </p>

            <p>1a. Patients receiving rifampin-based TB treatment.</p>
            <table class="uk-table">
                <tbody>
                    <tr>
                        <th>Preferred</th>
                        <td>DTG (Tivicay) BID + TDF/FTC (Truvada)</td>
                    </tr>
                    <tr>
                        <th>Alternative</th>
                        <td>
                            <ul>
                                <li>DTG (Tivicay) BID + TAF/FTC (Descovy)</li>
                                <li>DTG (Tivicay) BID + ABC/3TC</li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th>Frequency</th>
                        <td>Daily for both preferred and alternative</td>
                    </tr>
                    <tr>
                        <th>Note</th>
                        <td>Triumeq is a combination of DTG/ABC/3tc</td>
                    </tr>
                </tbody>
            </table>


            <p>1b. Patients receiving rifabutin-based TB treatment</p>
            <table class="uk-table">
                <tbody>
                    <tr>
                        <th>Preferred</th>
                        <td>DTG (Tivicay) + TDF/FTC (Truvada)</td>
                    </tr>
                    <tr>
                        <th>Alternative</th>
                        <td>
                            <ul>
                                <li>DTG (Tivicay) + TAF/FTC (Descovy)</li>
                                <li>DTG/ABC/3TC (Triumeq)</li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th>Frequency</th>
                        <td>Daily for both preferred and alternative</td>
                    </tr>
                    <tr>
                        <th>Note</th>
                        <td>The FDA does not recommend using TAF with rifampin or rifabutin</td>
                    </tr>
                </tbody>
            </table>

            <p>Abbreviations:</p>
            <ul>
                <li>NRTIs: nucleoside/-tide reverse transcriptase inhibitors</li>
                <li>NNRTIs: non-nucleoside reverse transcriptase inhibitors</li>
                <li>PIs: protease inhibitors</li>
                <li>/r: boosted with ritonavir</li>
                <li>TDF: Tenofovir disoproxil fumarate</li>
                <li>TAF: Tenofovir alafenamide</li>
                <li>FTC: Emtricitabine</li>
                <li>3TC: Lamivudine</li>
                <li>ABC: Abacavir</li>
                <li>ATV/r: Atazanavir/ritonavir</li>
                <li>DRV/r: Darunavir/ritonavir</li>
                <li>DTG: Dolutegravir</li>
            </ul>

            <p>Source:</p>
            <ul>
                <li>Above based on guidelines developed by the Department of Health and Human Services (DHHS) Panel on Guidelines for Use of Antiretroviral Agents for Adults and Adolescents and Use of Antiretroviral Drugs in Pregnant Women living with HIV and Interventions to Reduce</li>
                <li>Perinatal Transmission in the United States, last reviewed and updated October 29, 2024 (<a href="https://aidsinfo.nih.gov/guidelines">https://aidsinfo.nih.gov/guidelines</a>).</li>
            </ul>
         </div>

         <div id="option-content2" class="tab-content option-content">
            <p>
                <strong>
                    PI-based ART regimens
                </strong>
                (cannot be used with rifampin, must use with dose-adjusted rifabutin)
                
            </p>

            <p>2a</p>
            <table class="uk-table">
                <tbody>
                    <tr>
                        <th>Preferred</th>
                        <td>ATV/r + TDF/FTC (Truvada) </td>
                    </tr>
                    <tr>
                        <th>Alternative</th>
                        <td>
                            <ul>
                                <li>ATV/r + TAF/FTC (Descovy)</li>
                                <li>ATV/r + ABC/3TC</li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th>Frequency</th>
                        <td>Daily for both preferred and alternative</td>
                    </tr>
                </tbody>
            </table>


            <p>2b</p>
            <table class="uk-table">
                <tbody>
                    <tr>
                        <th>Preferred</th>
                        <td>DRV/r + TDF/FTC (Truvada) </td>
                    </tr>
                    <tr>
                        <th>Alternative</th>
                        <td>
                            <ul>
                                <li>DRV/r + TAF/FTC (Descovy)</li>
                                <li>DRV/r + ABC/3TC</li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th>Frequency</th>
                        <td>Daily for both preferred and alternative</td>
                    </tr>
                </tbody>
            </table>

            <p>Additional Notes:</p>
            <ul>
                <li>PI’s have high barrier to resistance. However, given rifabutin is given at half-dose when used with PI’s adherence to ART should be closely monitored. Poor adherence to PI’s while on rifabutin increases risk for rifampin resistance.</li>
                <li>The FDA does not recommend using TAF with rifampin or rifabutin.</li>
                <li>Cobicistat cannot be used with rifabutin.</li>
            </ul>

            <p>Abbreviations:</p>
            <ul>
                <li>NRTIs: nucleoside/-tide reverse transcriptase inhibitors</li>
                <li>NNRTIs: non-nucleoside reverse transcriptase inhibitors</li>
                <li>PIs: protease inhibitors</li>
                <li>/r: boosted with ritonavir</li>
                <li>TDF: Tenofovir disoproxil fumarate</li>
                <li>TAF: Tenofovir alafenamide</li>
                <li>FTC: Emtricitabine</li>
                <li>3TC: Lamivudine</li>
                <li>ABC: Abacavir</li>
                <li>ATV/r: Atazanavir/ritonavir</li>
                <li>DRV/r: Darunavir/ritonavir</li>
                <li>DTG: Dolutegravir</li>
            </ul>

            <p>Source:</p>
            <ul>
                <li>Above based on guidelines developed by the Department of Health and Human Services (DHHS) Panel on Guidelines for Use of Antiretroviral Agents for Adults and Adolescents and Use of Antiretroviral Drugs in Pregnant Women living with HIV and Interventions to Reduce</li>
                <li>Perinatal Transmission in the United States, last reviewed and updated October 29, 2024 (<a href="https://aidsinfo.nih.gov/guidelines">https://aidsinfo.nih.gov/guidelines</a>).</li>
            </ul>
         </div>

         <div id="option-content3" class="tab-content option-content">
            <p>
                <strong>
                    Choice for Pregnant Women living with HIV and with Active TB
                </strong>
            </p>

            <p>2a</p>
            <table class="uk-table">
                <tbody>
                    <tr>
                        <th>Notes</th>
                        <td>
                            <ul>
                                <li>Expert consultation advised.</li>
                                <li><strong>Options 1a</strong> and <strong>1b</strong> are currently preferred in pregnancy.</li>
                            </ul>
                        </td>
                    </tr>
                </tbody>
            </table>

            <p>Source:</p>
            <ul>
                <li>Above based on guidelines developed by the Department of Health and Human Services (DHHS) Panel on Guidelines for Use of Antiretroviral Agents for Adults and Adolescents and Use of Antiretroviral Drugs in Pregnant Women living with HIV and Interventions to Reduce</li>
                <li>Perinatal Transmission in the United States, last reviewed and updated October 29, 2024 (<a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium?view=full">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mycobacterium?view=full</a>).</li>
            </ul>
         </div>
    </div>
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
</html>
